Acceleron Named to the "Best Places to Work" List by The Scientist Magazine

Acceleron Named to the "Best Places to Work" List by The Scientist Magazine

June 4, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced that it was named to the 2013 “Best Places to Work in Industry” by The Scientist magazine in their 11th annual survey. The survey included responses from 240 companies. Survey participants were asked to assess their work environment according to 43 criteria in eight different categories including research environment, integrity, management, communications, job satisfaction, and training and development. Other companies ranked in the top ten included Genos Ltd, Vitae Pharmaceuticals, OpenEye Scientific Software, Inc., Wyatt Technology Corporation, Genentech (a member of the Roche Group), Millennium: The Takeda Oncology Company, Integrated DNA Technologies, Regeneron Pharmaceuticals, and Monsanto.

“Acceleron is honored to be named by The Scientist as one of the 2013 Best Places to Work,” said John Knopf, Ph.D., Chief Executive Officer and Founder of Acceleron. “As we aspire to discover and develop therapies that will transform the lives of people suffering from cancer and orphan diseases, we remain committed to maintaining a culture that empowers our employees to thrive and take deep pride in their contributions to advancing science and improving the lives of patients.”

About Acceleron

Acceleron is a privately-held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel protein therapeutics for orphan diseases and cancer. Acceleron's scientific approach takes advantage of its unique insight to discover first-in-class therapies based on the TGF-β protein superfamily. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company's internal GMP manufacturing capability to advance its therapeutic programs rapidly and efficiently. The investors in Acceleron include Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For further information on Acceleron, please visit www.acceleronpharma.com.

Acceleron Pharma:
Steven Ertel, 617-649-9234
Chief Business Officer
or
Media:
Suda Communications LLC
Maureen L. Suda, 585-387-9248